REVELATION BIOSCIENCES INC
For the period ended Dec 31, 2024. Filed Mar 6, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 6, 2025
REVB$4.11+5.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| December 31,2024 | December 31,2023 | |
|---|---|---|
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $6,499,018 | $11,991,701 |
| Deferred offering costs | — | 71,133 |
| Prepaid expenses and other current assets | 66,699 | 84,691 |
| Total current assets | 6,565,717 | 12,147,525 |
| Property and equipment, net | 56,332 | 65,084 |
| Total assets | $6,622,049 | $12,212,609 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $783,621 | $1,359,898 |
| Accrued expenses | 1,127,800 | 1,152,460 |
| Deferred underwriting commissions | — | 2,911,260 |
| Warrant liability | 2,246 | 141,276 |
| Total current liabilities | 1,913,667 | 5,564,894 |
| Total liabilities | 1,913,667 | 5,564,894 |
| Commitments and Contingencies (Note 4) | ||
| Stockholders’ equity: | ||
| Common Stock, $0.001 par value; 500,000,000 shares authorized at December 31, 2024 and December 31, 2023 and 522,223 and 16,484 issued and outstanding at December 31, 2024 and December 31, 2023, respectively | 522 | 16 |
| Additional paid-in-capital | 45,213,498 | 32,114,801 |
| Accumulated deficit | (40,505,638) | (25,467,102) |
| Total stockholders’ equity | 4,708,382 | 6,647,715 |
| Total liabilities and stockholders’ equity | $6,622,049 | $12,212,609 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.